Equities

ABVC Biopharma Inc

ABVC:NAQ

ABVC Biopharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.5265
  • Today's Change-0.016 / -2.93%
  • Shares traded69.06k
  • 1 Year change-52.99%
  • Beta0.7239
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year ABVC Biopharma Inc had revenues fall -84.28% from 969.78k to 152.43k, though the company grew net income from a loss of 16.42m to a smaller loss of 10.52m.
Gross margin-24.11%
Net profit margin-8,762.13%
Operating margin-6,259.18%
Return on assets-99.79%
Return on equity-287.44%
Return on investment-197.79%
More ▼

Cash flow in USDView more

In 2023, cash reserves at ABVC Biopharma Inc fell by 674.95k. Cash Flow from Financing totalled 3.92m or 2,570.99% of revenues. In addition the company used 4.24m for operations while cash used for investing totalled 360.19k.
Cash flow per share-1.50
Price/Cash flow per share--
Book value per share0.6882
Tangible book value per share0.6882
More ▼

Balance sheet in USDView more

ABVC Biopharma Inc has a Debt to Total Capital ratio of 18.73%.
Current ratio0.3343
Quick ratio--
Total debt/total equity0.2175
Total debt/total capital0.1873
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.